Edaravone Dexborneol provides neuroprotective effect by inhibiting neurotoxic activation of astrocytes through inhibiting NF-κB signaling in cortical ischemia

Brain Research Bulletin, Journal Year: 2024, Volume and Issue: 218, P. 111097 - 111097

Published: Oct. 10, 2024

Edaravone Dexborneol (EDB), comprised of edaravone and (+)- bornel, has been demonstrated to have synergistic effects antioxidant anti-inflammatory, which makes it be applied for stroke as a protectant. However, the underlying mechanism neuroprotection EDB not fully elucidated. Increasing evidence shown that neurotoxic A1 astrocytes were closely related neuronal death after cerebral ischemia. whether could provide by modulating activation yet The present study aimed explore afforded polarization down-stream signaling We first validated neuroprotective in mice suffering focal ischemia via evaluating behavioral test, infarct volumes survival. As signaling, our data further showed alleviated suppressing inhibition NF-κB pathway vitro. Additionally, administration reduced number reactive above findings provided effect inhibiting animal model ischemia, indicated EDB-mediated phenotypic regulation is potential research direction promote neurological recovery central nervous system (CNS) diseases.

Language: Английский

---

Edaravone dexborneol protected neurological function by targeting NRF2/ARE and NF-κB/AIM2 pathways in cerebral ischemia/reperfusion injury

Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16

Published: April 25, 2025

Edaravone dexborneol (Eda-Dex), a promising neuroprotectant composed of edaravone and (+)-borneol, has been clinically applied in stroke treatment. However, the mechanism action Eda-Dex remains unclear. A rat model cerebral ischemia/reperfusion injury (CIRI) was created through middle artery occlusion. Neurological scoring, TTC staining, laser speckle imaging were used to assess neurological deficits, infarct size blood flow (CBF). Behavioral tests, including open field test, elevated plus maze, novel object recognition conducted animal behavior. Western blotting ELISA employed levels expression components NRF2/ARE NF-κB/AIM2 pathways specific cytokines. The oxidative stress markers analyzed via commercially available kits. HE Nissl immunohistochemistry pathological alterations brain. dramatically reduced deficit score size, increased CBF, attenuated anxiety-like behavior improved cognitive function CIRI rats. significantly relieved inflammatory response it upregulated NRF2, NQO1, HO-1, SLC7A11 downregulated NF-κB, AIM2, ASC caspase 1 infarcted Moreover, clearly damage, rescued neurons, activation microglia astrocytes. results this study confirm that exerts neuroprotective effects by synergistically inhibiting inflammation

Language: Английский

---

Ischemic Stroke Treatment by Vagus Nerve Stimulation: A Comprehensive Review of Mechanisms, Clinical Efficacy, and Future Directions

Journal of Neurorestoratology, Journal Year: 2025, Volume and Issue: unknown, P. 100209 - 100209

Published: April 1, 2025

Language: Английский

---

Edaravone dexborneol for the treatment of acute ischemic stroke: A systematic review and meta-analysis

The Neuroradiology Journal, Journal Year: 2025, Volume and Issue: unknown

Published: May 8, 2025

Background Edaravone dexborneol has been developed as a novel neuroprotective agent and showed promising result in treatment of stroke. The current meta-analysis aimed to assess the feasibility efficacy edaravone Method We performed systematic review literature four electronic databases. Binary outcomes were analyzed through risks ratio (RR) 95% confidence interval (CI), while continuous standardized mean difference (SMD) CI. Also, we did subgroup analysis show more safety dimensions. Results Five studies with total 2415 patients included. There 1119 group 1216 control group. 90-mRS 0–1 (RR 1.17 [95% CI 1.09–1.25]; p < 0.0001) 90-day mRS 0–2 1.12 1.07–1.18]; statistically significant higher intervention compared was no between concerning 0–3 1.03 0.99–1.06]; = 0.07), mortality rate 0.71 0.45–1.11]; 0.13), serious adverse events 0.91 0.72–1.16]; 0.45), NIHSS score ≤1 at days 14 0.96; 0.69), 30 1.08; 0.18), 90 1.06; 0.15). No heterogeneity effect seen analysis, any potential discrepancies addressed by sensitivity analysis. Conclusion can be favorable option for However, randomized controlled trials are required confirm our findings.

Language: Английский

---

Synergistic effects of neuroprotective drugs with intravenous recombinant tissue plasminogen activator in acute ischemic stroke: A Bayesian network meta-analysis

PLoS ONE, Journal Year: 2024, Volume and Issue: 19(12), P. e0311231 - e0311231

Published: Dec. 2, 2024

Neuroprotective drugs as adjunctive therapy for adults with acute ischemic stroke (AIS) remains contentious. This study summarizes the latest evidence regarding benefits of neuroprotective agents combined intravenous recombinant tissue plasminogen activator (rt-PA) thrombolysis. conducted a structured search PubMed, Cochrane Library, EMBASE, Wanfang Data, and CNKI databases from their inception to March 2024. Grey literature was also searched. The outcomes included efficacy (National Institutes Health Stroke Scale (NIHSS) score Barthel Index (BI) score) safety (rate adverse reactions). A total 70 randomized controlled trials were selected this network meta-analysis (NMA), encompassing 4,140 patients AIS treated using different plus RT-PA, while 4,012 in control groups. top three treatments NIHSS scores at 2-week follow-up Edaravone Dexborneo 0.9 mg/kg rt-PA, HUK rt-PA. Dl-3n-butylphthalide rt-PA ranked BI follow-up. lowest effect rates 0.6 due excellent profiles. Compared alone, combination Edaravone+rt-PA, Dexborneol+rt-PA, HUK+rt-PA, Dl-3n-butylphthalide+rt-PA, Ganglioside GM1+rt-PA have shown superior efficacy. NMA suggest that therapies can offer better AIS. results support potential integration these into standard treatment, aiming improved patient personalized therapeutic approaches.

Language: Английский

---